Forteo ® (teriparatide [rDNA origin] injection)

20-mcg daily dose in a 2.4-mL prefilled delivery device

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

Adverse Reactions Associated with Abruptly Stopping FORTEO® (teriparatide [rDNA origin]

Safety concerns associated with temporary interruption or abrupt discontinuation of Forteo therapy have not been identified

Lilly has not identified any safety concerns, including adverse reactions or side effects, associated with temporary interruption or withdrawal of Forteo® (teriparatide [rDNA origin] injection) therapy during our clinical studies or follow-up analyses (Neer, 2001; Orwoll, 2003; Lindsay, 2004; Saag, 2007; Saag 2009; Silverman, 2013).

It is not known how stopping and starting teriparatide effects how it works as teriparatide was studied as a once daily injection without interruptions for 24 months (Forteo Package Insert, 2012).

Inform your physician if you had to stop teriparatide for any period of time.

Enclosed Prescribing Information

FORTEO® (teriparatide [rDNA origin] injection), Lilly

The published references below are available upon request by contacting 1-800-LillyRx.

References

FORTEO® [Package Insert]. Indianapolis, IN: Eli Lilly and Company; 2012.

Lindsay R, Scheele WH, Neer R, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med. 2004;164(18):2024-2030.

Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434-1441.

Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003;18(1):9-17.

Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357(20):2028-2039.

Saag KG, Zanchetta JR, Devogelaer J-P, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009;60(11):3346-3355.

Silverman S, Miller P, Sebba A, et al. The Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) study: 2-year nonvertebral fragility fracture results. Osteoporosis Int. 2013;24(8):2309-2317.

Date of Last Review: February 12, 2017

Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 9am - 8pm ET

Or you can

Ask us a question Chat with us

Submit a question

Visit Us @LillyMedical